AimVion is a privately held research and development company focused on peptide based drugs for inflammatory and autoimmune diseases. The company was founded in 2015 based on its proprietary technology for a new class of anti-inflammatory peptides derived from human genetic elements. AimVion brings a team of experienced scientists, researchers and businessmen together to fulfill the need for better, safer and cheaper anti-inflammatory drugs of the future.
The company has quickly established a portfolio of anti-inflammatory peptides in pre-clinical development stage and has focus on Rheumatoid Arthritis and Multiple Sclerosis as its primary indications.